Does having cancer decrease the risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.

Keynote Speaker: Jane Driver (Brigham and Women's Hospital)
Speakers: Kurt Brunden (University of Pennsylvania), Gary Landreth (ReXceptor), David M. Roy (Memorial Sloan Kettering Cancer Center), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Hui Zheng (Baylor College of Medicine), Claes Wahlestedt (University of Miami, Miller School of Medicine), Carlos Buesa, PhD (Oryzon)